Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Milan, Italy; University of Milan, School of Medicine, Italy.
Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Milan, Italy.
Breast. 2018 Feb;37:207-214. doi: 10.1016/j.breast.2017.03.010. Epub 2017 Mar 28.
Immunoediting represents a complex and dynamic process involving cancer and immune system cells, composed by three intertwined phases: elimination, equilibrium and escape. A large number of immune cell subtypes are involved, each playing a peculiar role in interacting with cancer cells: cytotoxic CD8 T cells play a main role in cancer killing by inducing tumor cell death, while FOXP3+ T-regulatory cells represent an immune-inhibitory cell subtype. The evaluation of tumor infiltrating lymphocytes (TILs) in H&E routine samples has been shown to represent a reliable surrogate of the immune anti-tumor activity and a robust independent prognostic biomarker in breast cancer (BC) patients, especially in the Tripe Negative and HER2+ subtypes. The present review addresses the mechanisms of breast cancer immunoediting, its cell complexity and prognostic/predictive relevance, providing evidence that TILs represent one the most promising biomarkers for BC patients.
免疫编辑代表一个复杂和动态的过程，涉及癌症和免疫系统细胞，由三个相互交织的阶段组成：消除、平衡和逃逸。大量的免疫细胞亚型参与其中，每种细胞在与癌细胞相互作用中都起着独特的作用：细胞毒性 CD8 T 细胞通过诱导肿瘤细胞死亡在癌症杀伤中起主要作用，而 FOXP3+T 调节细胞则代表一种免疫抑制细胞亚型。在 H&E 常规样本中评估肿瘤浸润淋巴细胞 (TILs) 已被证明是一种可靠的替代物，可以代表乳腺癌 (BC) 患者的免疫抗肿瘤活性和强大的独立预后生物标志物，尤其是在三阴性和 HER2+ 亚型中。本综述探讨了乳腺癌免疫编辑的机制、其细胞复杂性和预后/预测相关性，为 TILs 作为 BC 患者最有前途的生物标志物之一提供了证据。
